

# EpiSwitch® CST COVID-19 Severity Risk Report

## Personalized Immune Health 3D-Genetic Profile

### Patient Name

**Peterson, Janette**

### Date of Birth

**22-DEC-1975**

### Patient Information

Gender	Female
Patient ID	D000097422
Medical Record #	c14456d0
Report #	COVID0254

### Physician Release

Physician Name	Christopher Smith, MD, MS
Account Name	XXX-XXX-XXX-XXX
Address	[Address line] [City], [State] [Zip]
Phone	811-555-4210
Account Ref	FL

### Specimen Information

Report Date	28-FEB-2021
Receipt Date	28-FEB-2021
Collection Date	20-FEB-2021
Specimen Type	WB EDTA K3
Specimen ID	D000097422

## EpiSwitch® COVID-19 Severity Risk Score

Your Risk Level

Average Risk

High Risk

The **EpiSwitch COVID-19 Severity Test** result for this specimen is in the **high-risk range**. This individual is predicted to be at high risk to require critical care (ICU) in response to an **UNTREATED** SARS-CoV-2 infection. This result does not inform on the risk of becoming infected. This result should be considered along with other clinical features for interpretation by a licensed medical professional.

## EpiSwitch COVID-19 Severity Risk Assay Description

**EpiSwitch COVID-19 Severity Test** evaluates six unique Chromosome Conformational Signatures (CCSs), that are prognostic for critical disease associated with genetic loci that have been shown to affect immune health.

**Intended Use:** The test is intended to identify people who are at the highest risk of critical COVID-19 disease resulting from untreated SARS-CoV-2 virus. People with a high risk of severe or critical disease may benefit from increased infection mitigation and in the event of infection, early use of medications or other interventions. An average risk with a lower score should not be construed as lower severity probability; complications not requiring critical care are possible. The test is not intended to evaluate an individual's risk of infection.

### References

- Hunter, E., Koutsothanasi, C., et al. (2021). 3D genomic capture of regulatory immuno-genetic profiles in COVID-19 patients for prognosis of severe COVID disease outcome. *BioRxiv*. <https://doi.org/10.1101/2021.03.14.435295>. Co-published by authors from Oxford BioDynamics, University of Oxford, West Hertfordshire NHS Trust, Oregon Health & Science University, and Norwich Medical School at the University of East Anglia.
- Hunter, E., Koutsothanasi, C., et al. (2021). Development and validation of blood-based prognostic biomarkers for severity of COVID disease outcome using EpiSwitch 3D genomic regulatory immuno-genetic profiling. *MedRxiv*. <https://doi.org/10.1101/2021.06.21.21259145>. Co-published by authors from Oxford BioDynamics, University of Oxford, West Hertfordshire NHS Trust, Oregon Health & Science University, and Norwich Medical School at the University of East Anglia.
- Clinical Spectrum of SARS-CoV-2 Infection. <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>
- Therapeutic Management of Adults With COVID-19. <https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/>

**Disclaimer:** The EpiSwitch COVID-19 Severity Test was developed, and its performance characteristics determined by the clinical lab. It has not been cleared or approved by the US Food and Drug Administration. The FDA does not require this test to go through premarket FDA review. This test is used for clinical purposes. It should not be regarded as investigation or for research. The laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing. Decisions regarding care and treatment should not be based on a single test such as this test. Rather, decisions on care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's condition, including other clinical tests, in accordance with the standard of care in a given community.

This test was performed at **NEXT Bio Research Services, LLC, 11601 Ironbridge Rd, Chester, VA 23831 – CLIA #41D2104154**. For questions about the report, email [CST.TEST@myOBDX.com](mailto:CST.TEST@myOBDX.com) or call **888-236-8896**.

Medical Director Signature

Date (MM/DD/YYYY)



# EpiSwitch® CST COVID-19 Severity Risk Report

## Personalized Immune Health 3D-Genetic Profile

### Patient Name

**Peterson, Janette**

### Date of Birth

**22-DEC-1975**

## EpiSwitch® COVID-19 Severity Risk Score

Your Risk Level

Average Risk

High Risk

The **EpiSwitch COVID-19 Severity Test** result for this specimen is in the **average-risk range**. This individual is predicted to be at average risk to require critical care (ICU) in response to an **UNTREATED** SARS-CoV-2 infection. This result does not inform on the risk of becoming infected. This result should be considered along with other clinical features for interpretation by a licensed medical professional.

### Patient Information

Gender	Female
Patient ID	D000097422
Medical Record #	c14456d0
Report #	COVID0254

### Physician Release

Physician Name	Christopher Smith, MD, MS
Account Name	XXX-XXX-XXX-XXX
Address	[Address line] [City], [State] [Zip]
Phone	811-555-4210
Account Ref	FL

### Specimen Information

Report Date	28-FEB-2021
Receipt Date	28-FEB-2021
Collection Date	20-FEB-2021
Specimen Type	WB EDTA K3
Specimen ID	D000097422

## EpiSwitch COVID-19 Severity Risk Assay Description

**EpiSwitch COVID-19 Severity Test** evaluates six unique Chromosome Conformational Signatures (CCSs), that are prognostic for critical disease associated with genetic loci that have been shown to affect immune health.

**Intended Use:** The test is intended to identify people who are at the highest risk of critical COVID-19 disease resulting from untreated SARS-CoV-2 virus. People with a high risk of severe or critical disease may benefit from increased infection mitigation and in the event of infection, early use of medications or other interventions. An average risk with a lower score should not be construed as lower severity probability; complications not requiring critical care are possible. The test is not intended to evaluate an individual's risk of infection.

### References

- Hunter, E., Koutsothanasi, C., et al. (2021). 3D genomic capture of regulatory immuno-genetic profiles in COVID-19 patients for prognosis of severe COVID disease outcome. *BioRxiv*. <https://doi.org/10.1101/2021.03.14.435295>. Co-published by authors from Oxford BioDynamics, University of Oxford, West Hertfordshire NHS Trust, Oregon Health & Science University, and Norwich Medical School at the University of East Anglia.
- Hunter, E., Koutsothanasi, C., et al. (2021). Development and validation of blood-based prognostic biomarkers for severity of COVID disease outcome using EpiSwitch 3D genomic regulatory immuno-genetic profiling. *MedRxiv*. <https://doi.org/10.1101/2021.06.21.21259145>. Co-published by authors from Oxford BioDynamics, University of Oxford, West Hertfordshire NHS Trust, Oregon Health & Science University, and Norwich Medical School at the University of East Anglia.
- Clinical Spectrum of SARS-CoV-2 Infection. <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>
- Therapeutic Management of Adults With COVID-19. <https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/>

**Disclaimer:** The EpiSwitch COVID-19 Severity Test was developed, and its performance characteristics determined by the clinical lab. It has not been cleared or approved by the US Food and Drug Administration. The FDA does not require this test to go through premarket FDA review. This test is used for clinical purposes. It should not be regarded as investigation or for research. The laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing. Decisions regarding care and treatment should not be based on a single test such as this test. Rather, decisions on care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's condition, including other clinical tests, in accordance with the standard of care in a given community.

This test was performed at **NEXT Bio Research Services, LLC, 11601 Ironbridge Rd, Chester, VA 23831 – CLIA #41D2104154**. For questions about the report, email [CST.TEST@myOBDX.com](mailto:CST.TEST@myOBDX.com) or call **888-236-8896**.

Medical Director Signature

Date (MM/DD/YYYY)

